Arrowhead Pharmaceuticals (ARWR) Assets Average (2011 - 2026)

Arrowhead Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• Quarterly Assets Average rose 49.68% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 49.68% YoY) and the FY2025 annual result came in at $1.3 billion, up 32.53% from the prior year.
• Assets Average was $1.9 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $1.5 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.9 billion in Q1 2026 and bottomed at $671.1 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $891.4 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average fell 12.1% — and 2025, when it soared 63.6%.
• Arrowhead Pharmaceuticals' Assets Average stood at $791.7 million in 2022, then retreated by 12.1% to $695.9 million in 2023, then soared by 54.72% to $1.1 billion in 2024, then jumped by 38.82% to $1.5 billion in 2025, then rose by 29.54% to $1.9 billion in 2026.
• Business Quant data shows ARWR's Assets Average at $1.9 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.